PLX EBITDA Growth
Protalix Biotherapeutics Inc · EBITDA Growth
PLX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported149.10%period ending
PLX TTM EBITDA YoY % (-654.55% → 149.10%)
Year-over-year change
High-resolution chart · PNG
PLX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 149.1044% | |
| 211.7861% | |
| -142.8067% | |
| 237.0039% | |
| 188.6639% | |
| -34.4891% | |
| -49.6331% | |
| -140.4713% | |
| -183.2284% | |
| 195.9701% | |
| 220.0723% | |
| 221.5452% | |
| 219.031% | |
| 30.2041% | |
| 39.9521% | |
| -30.6112% | |
| -11.8748% | |
| -323.3204% | |
| -503.4607% | |
| -349.8884% | |
| -310.2408% | |
| -353.9526% | |
| 151.1906% | |
| 606.3047% | |
| 454.6528% | |
| 167.8891% | |
| -360.9226% | |
| 102.1616% | |
| 95.2938% | |
| 89.0155% | |
| 97.3927% | |
| 61.2031% | |
| 54.128% | |
| 74.5668% | |
| -136.5932% | |
| -104.6036% | |
| -109.9031% | |
| -192.4581% | |
| -22.2911% | |
| -63.3436% | |
| -48.878% | |
| -31.2188% | |
| -15.1165% | |
| 17.5649% | |
| 11.3948% | |
| 18.4707% | |
| 7.0291% | |
| -6.0277% | |
| -3.7825% | |
| -280.3301% | |
| -175.4717% | |
| -225.6357% | |
| -123.6224% | |
| 76.3942% | |
| 69.1838% | |
| 80.5256% | |
| 66.4566% | |
| 11.6387% | |
| 22.5042% | |
| -12.1362% | |
| 14.7215% | |
| 1.7549% | |
| -18.4462% | |
| -52.7044% | |
| -62.9412% | |
| -53.0235% | |
| -31.0844% | |
| 5.6193% | |
| 1.2329% | |
| 21.0272% | |
| 7.812% | |
| 19.1245% | |
| 7.4726% | |
| -46.2338% | |
| -50.6894% | |
| -280.7802% | |
| -387.8692% | |
| -1,045.4696% | |
| -17,546.3653% | |
| -7,337.1611% | |
| -4,555.2895% | |
| -1,004.8181% | |
| 43.6566% | |
| 45.538% | |
| 37.4234% | |
| -2.9765% | |
| -12.3459% | |
| -20.6981% | |
| -11.4828% | |
| 10.769% | |
| 11.1014% | |
| 43.9477% | |
| 47.4022% | |
| 50.1795% | |
| 43.1812% | |
| 24.1999% | |
| 6.4098% | |
| 1.4185% | |
| 23.5271% | |
| -48.4826% |